FindTrial
Sign In

Study on the safety and efficacy of HIFU combined with radiotherapy for the treatment of malignant solid tumors

Study on the safety and efficacy of HIFU for residual/recurrent malignant solid tumor after radiotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119125
Enrollment
Unknown
Registered
2026-02-24
Start date
2022-12-03
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant solid tumor

Interventions

Malignant solid tumor observation group:None

Sponsors

Mianyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. For patients with pathologically confirmed malignant solid tumors, enhanced CT/MRI/PET-CT within 6 months after radiotherapy indicated residual lesions or recurrence after 6 months, and HIFU ultrasound localization had a safe acoustic channel; 2. The skin within the HIFU treatment area was intact; 3. Chemotherapy or other systemic treatments have been completed for more than 2 months; 4. The ECOG score is 1-2, and the expected survival period is greater than 3 months.

Exclusion criteria

Exclusion criteria: 1. After assessment, it was found that there is no safe acoustic channel for HIFU ultrasound positioning. 2. If the ablation lesion is located in the liver, the liver function should be evaluated as grade C by the Child classification system. 3. There are more suitable surgical resection methods or more appropriate radiofrequency ablation treatment plans.

Design outcomes

Primary

MeasureTime frame
Skin toxicity;Liver function;—

Countries

China

Contacts

Public ContactDu Xiaobo

Mianyang Central Hospital

duxiaobo2005@126.com+86 816 279 9241

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026